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The development of a validated method, applicable for the measurement of tryptophan (TRP) 
and serotonin (5-HT), and that of the neuroprotective branch of the kynurenine pathway from 
several different biological matrices, including mouse brain, is described. Following the spectral 
analysis of the metabolites, they were quantified with reversed-phase high-performance liquid 
chromatography (HPLC), using separate internal standards (ISs) for UV (3-nitro-L-tyrosine) 
and fluorescent (the newly utilized 4-hydroxyquinazoline-2-carboxylic acid) detectors. With 
regard to validation parameters, selectivity, linearity, limit of detection, limit of quantification, 
precision and recovery were determined. Although the linearity ranges were different for the 
assessed matrices, the correlation coefficient was > 0.999 in each case. Furthermore, good intra- 
and inter-day precision values were obtained with coefficient of variation < 5%, and bias < 
6.5% (except the 5-HT level in brain samples), respectively. The recoveries varied between 
82.5% and 116%. The currently developed methods yield opportunities for the assessment of 
concentration changes in the TRP metabolism from a wide range of biological matrices, 
therefore they may well be utilized in future clinical and preclinical studies, especially in view 
that so many metabolites with the application of ISs have not been detected from mouse brain 





Tryptophan (TRP), the essential amino acid obtained from diet, is mainly metabolized through 
the kynurenine (KYN) pathway (KP; Fig. 1), whereas only a small proportion of it is 
catabolized to the neurotransmitter serotonin (5-HT) [1]. Recently, a special attention has been 
paid to the KP in neuroscience research, especially in light of the well documented alterations of 
the pathway in numerous neurological disorders, such as Parkinson’s disease, Alzheimer’s 
disease, multiple sclerosis and schizophrenia [2–6]. Accordingly, several methods have been 
developed for the quantification of TRP and its metabolites, including those with multiple-step 
sample preparation, pre- or post-column derivatization or those needing complex instrumental 
background (e.g., high-performance liquid chromatography (HPLC) mass spectrometry, gas 
chromatography mass spectrometry) [7]. The assessment of TRP, KYN and kynurenic acid 
(KYNA), usually designated as the neuroprotective branch of the KP, may yield meaningful 
information in several preclinical and clinical studies [1]. The detection and quantification of 
these metabolites can be achieved in an easier way compared to the other compounds of the KP 
[7–9]. The partial assessment of the KP has been described with different HPLC methods, using 
several detection techniques, including UV detector (UVD) and fluorescence detector (FLD) 
[9,10], diode array detector [11], electrochemical detector [12] or mass spectrometry [13,14], 
targeting different biological matrices: human serum or plasma, and cerebrospinal fluid (CSF) 
[5,13–16], murine serum or plasma [9,14], and brain [9,17]. The heterogeneity of the methods is 
further increased by the application of internal standards (ISs), although only some (37.7%) of 
the articles of interest (Supplementary file, Table S1) applied ISs at all, and none of them 
utilized ISs separately for each detector. This especially makes sense when in addition to the 
obviously necessary features of ISs (stability, pure form, absence in native sample, or no 
interference with another compound) [18,19], two often neglected characteristics are also taken 
into account: compatibility with the detector response and similarity in structure and properties 
with the analyzed compounds. Accordingly, the application of different ISs is required for each 
detector as the concentrations are calculated from a calibration plot where the concentration 
values are plotted against the response ratios. In light of these requirements, 3-nitro-L-tyrosine 
(3NLT) is not appropriate as an IS for the fluorescent detectable compounds TRP, 5-HT and 
KYNA. Consequently, the application of 4-hydroxyquinazoline-2-carboxylic acid (HCA) 
emerged as a new IS for the measurement of TRP, 5-HT and KYNA, with a special relevance to 
the latter one due to the similarities in their structure, which probably enables the detection of 
HCA at the same wavelength as KYNA, without affecting the running time of the sample. 
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3NLT has already been applied widely as an IS for UVD, as its structure is similar to that of 
KYN (Fig. 1). 
The aim of the current study was to present a simple, rapid, precise, robust and economical 
method (95% water in the mobile phase) for the simultaneous quantification of TRP, 5-HT 
(present in detectable amounts only in the mouse brain), KYN and KYNA by HPLC-UVD and 
FLD, using ISs for each detector (3NLT for the UVD, and HCA for the FLD), following a 
complete spectral analyses of each compound. To demonstrate the robustness of the method, the 
validation process was completed on four different biological matrices ( mouse plasma and 
brain, human plasma and CSF) according to the ICH and FDA guidelines [20, 21]. Furthermore, 
to verify the applicability of the currently developed methods, all of the metabolites of interest 
were quantified from the above-mentioned matrices, and the obtained concentration values were 
compared with the available literature data. 
 
2. Material and methods 
2.1. Instrumentation and reagents  
The chromatographic analyses were performed using an Agilent 1100 HPLC system (Santa 
Clara, CA, USA) with Agilent G1314A UVD and G1321A FLD. The spectral analyses of the 
UV-detected compounds were made with an Agilent 8453 UV-Vis Spectroscopy System (Santa 
Clara, CA, USA). The reference compounds TRP, 5-HT, KYN, KYNA, 3NLT; perchloric acid 
(PCA), zinc acetate (ZnAc) and phosphoric acid were purchased from Sigma-Aldrich (Saint 
Louis, MO, USA). Acetonitrile (ACN) was obtained from Scharlau (Barcelona, Spain) and 
acetic acid from VWR International (Radnor, PA, USA). The di-sodium-hydrogen phosphate 
dihydrate was obtained from VWR International (Radnor, PA, USA) and potassium dihydrogen 
phosphate from Applichem Panreac (Darmstadt, Germany). The IS used for the FLD (HCA) 
was synthesized at the Department of Pharmaceutical Chemistry, University of Szeged, 
involving the ring closure of anthranilamide with diethyl oxalate, followed by the hydrolysis of 
the ester function [33]. 
2.2. Collection and preparation of biological samples 
Mouse plasma samples and mouse brain tissues were obtained from 3-4 months old C57Bl/6 
mice. The blood samples were collected into Na-EDTA-containing tubes and centrifuged at 
3500 RPM for 10 min and the resulting plasma samples were stored at -80°C until analysis. The 
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frozen plasma was thawed at room temperature, then deproteinized with 0.5 M PCA solution 
(1:1 v/v), containing both ISs at final concentration of 100 nM HCA and 2 µM 3NLT, and 
centrifuged for 10 min at 12000 RPM at 4°C. For the validation process, the individual samples 
were pooled, whereas for the demonstration of the applicability of the method and comparison 
of the obtained results with those from the literature, the metabolites of interest were measured 
from 8 independent samples. Regarding the freshly prepared mouse brain samples, the tissues 
were weighed and then sonicated for 90 s in an ice-cooled solution, 1:5 w/v, comprising 0.5 M 
PCA and the 2 ISs in an Eppendorf tube. The content of the Eppendorf tube was centrifuged for 
10 min at 12000 RPM at 4°C. For the validation process, pooled brain homogenates were 
applied, whereas the applicability of the method was tested on 8 independent striatum, cortex 
and hippocampus, obtained from the same mice as used for plasma sample measurements. The 
animal experiments were authorized by the local ethical committee of University of Szeged 
with adherence to the NIH guidelines and the EU directive 2010/63/EU for the protection of 
animals used for scientific purposes. Human plasma samples were obtained from 26-39 years 
old healthy subjects following obtaining written informed consent. Sample handling was almost 
the same as in case of mouse plasma samples, only the deproteinization process differed 
somewhat (the ratio of plasma and 0.5 M PCA solution was 1:3 v/v). The assessment of the 
applicability of the method was also carried out on 8 independent samples. The CSF samples 
were taken from 17-71 years old patients with headache who were initially suspected to have 
subarachnoid hemorrhage and underwent a spinal tap, but the CSF analysis was negative. 
Written informed consent was also obtained in each case. For the CSF samples, the same 
preparation procedure was applied as in cases of plasma samples, except using a dilution of 5:6 
v/v. The applicability of the method was also tested on 8 independent CSF samples. All the 
human samples were obtained with the approval of the local Ethical Committee of the 
University of Szeged (46/2014), adhering to the tenets of the most recent revision of the 
Declaration of Helsinki. 
2.3. Chromatographic conditions 
Chromatographic separations were performed on a reversed-phase C18 column (Kinetex, 150 x 
4.6 mm I.D., 5 µm particle size; Phenomenex Inc., Torrance, CA, USA) after passage through a 
pre-column (SecurityGuard, 4 x 3.0 mm I.D., Phenomenex Inc., Torrance, CA, USA) with a 
mobile phase composition of 200 mM ZnAc solution at pH of 6.2 for plasma and CSF samples, 
and at pH of 5.8 for brain samples, adjusted with acetic acid. The organic component (ACN) in 
the mobile phase was 5%, and the solution was filtered through a cellulose membrane with 0.2 
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m pore size. The flow rate was 1.2 ml/min and 20 µl of the plasma supernatants were injected, 
whereas in case of CSF and brain homogenate the injection volume was 50 µl. The application 
of ZnAc at such high concentration as 200 nM was necessary – focusing on the parallel 
prevention of precipitation as well – in light of the considerable increase of the fluorescence 
intensity of KYNA, which seems essential for its detection above limit of quantification (LOQ; 
Supplementary file, Fig. S3A). With the careful use of ZnAc at 200 nM, we did not experience 
precipitation and the lifespan of the applied column was not affected as well. The UV-Vis 
spectra data were collected from 200-800 nm in cases of KYN and 3NLT to determine the 
optimal wavelengths for measurements (Supplementary file Fig. S1). 
The determination of optimal wavelengths in case of FLD was carried out via the collection of 
spectral data in the ranges of 220‒380 nm (excitation) and 300‒495 nm (emission) for each 
fluorescent compound, i.e., TRP, 5-HT, KYNA, and HCA (Supplementary file, Fig. S2A, B, C, 
D). 
2.4. Method validation 
The investigated validation parameters were selectivity, linearity, limit of detection (LOD), 
LOQ, precision and recovery, respecting the ICH [20] and FDA [21] guidelines. As insufficient 
amount of sample was obtained from one animal (especially in case of mouse plasma), 
following the recommendations provided by the FDA [21], pooled samples were used in each 
case, for constancy of validation process. 
2.4.1. Calibration curve and linearity  
Stock solutions with the concentration of 100 µM were prepared by dissolving accurately 
weighed standard compounds in 0.5 M PCA solution, except the KYNA, which was dissolved 
in phosphorous buffer, with pH set at 6.2 with 85% phosphoric acid, due to solubility issues. A 
series of working solutions (WS) of the analytes with different concentration ranges for each 
matrix was prepared containing the ISs at final concentration of 2 µM for 3NLT and 100 nM for 
HCA. For the calibration curve, LOD and LOQ values, six calibration standards (CSs) were 
prepared by spiking the respective WSs into blank biological matrices, i.e., blank human plasma 
and CSF, and blank mouse plasma, respecting the dilution ratios presented above. With regard 
to mouse brain samples, the first step was the homogenization of the respective brain regions, 
and thereafter the supernatant was added the appropriate amount of the WSs. TRP, 5-HT, KYN 
and KYNA were prepared in the presented final concentration ranges (Table 1). The peak area 
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response ratios were plotted against the corresponding concentration, and the linear regression 
computations were carried out by the least square method with the freely available R software 
(R Development Core Team, 2002). The same procedure was applied for the preparation of the 
quality controls (QCs), i.e., spiking the blank biological matrices with the appropriate solutions, 
containing the analytes in three different concentration levels (low (LOQ), medium and high; 
Table 3) for performing the accuracy assays. Both CSs and QCs were prepared freshly, on the 
day of the measurements, whereas stock solutions and WSs were stored at –80ºC. 
 
3. Results and discussion 
3.1. Selection of the excitation and emission wavelengths 
As a result of absorbance analyses for KYN and 3NLT (Supplementary file, Fig. S1) the 
wavelength of the UVD was set to 365 nm when pH was 6.2, whereas a slight maximum 
absorbance shift was observed at pH 5.8, therefore 360 nm was applied in this case. Following 
spectral analyses in case of fluorescent detection, the excitation and emission wavelengths at pH 
6.2 were set to 246 and 396 nm for the determination of KYNA and HCA, and to 220 and 410 
nm for the determination of TRP, whereas at pH 5.8 the excitation and emission wavelengths 
were set to 239 and 400 nm for the determination of 5-HT, KYNA and HCA, and to 220 and 
355 nm for the determination of TRP (Supplementary file, Fig. S2). 
3.2. Utilization of two internal standards and selectivity of the applied methods 
Several methods have already been published for the quantification of TRP and some of its 
metabolites (Supplementary file, Table S1), but from the published articles, only our research 
group reported the use of the 3NLT, when quantifying the analytes of interest from brain 
samples via the application of an Onyx Monolithic C18 column (100 mm× 4.6 mm I.D., 
Phenomenex Inc., Torrance, CA, USA) [9]. Indeed, the monolith column provided a good 
running time (7 min, [9]), but the introduction of the novel IS (HCA) for the FLD led to co-
elution on the monolithic column (Supplementary file, Fig. S4) which resulted in the necessary 
change of the column. Accordingly, Kinetex C18 column was chosen with the aim of the 
parallel improvement of resolution. Although this novel setup with the optimization of flow rate 
and detection wavelengths was found to be suitable for measurements from plasma and CSF 
samples with appropriate selectivity and signal amplitude (Fig. 2), in case of mouse brain 
samples, an interfering peak was detected causing co-elution with both UVD and FLD (Fig. 3A, 
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B). Accordingly, a further adjustment (i.e., the change of pH value of the mobile phase from 6.2 
to 5.8, Fig. 3A, B) should be carried out to regain the appropriate selectivity (Supplementary 
file, Fig. S4). The further reduction of the pH considerably decreases the signal amplitude of 
KYNA, so it should be avoided (Supplementary file, Fig. S3B). 
3.3. Method validation 
3.3.1. Linearity  
With regard to the ranges for external standards, it was kept in mind that under pathological or 
treatment conditions, a considerably large alteration may occur compared to the physiological 
values detected in different biological matrices. Accordingly, we tried to set up a relatively wide 
concentration range for external standards focusing at carrying out measurements with good 
linearity as well. The applied ranges mentioned in the Table 1 were confirmed to be linear in all 
cases, with a correlation coefficient > 0.999 for each compound when either FLD or UVD was 
applied.  
3.3.2. LOD and LOQ 
LOD and LOQ were determined based on the guidelines [20, 21] calculating by the Equation 1, 
where σ is the standard error of the intercept and S’ is the slope of the calibration curve of the 
analyte, presented in Table 1. 
LOD = 3.3·σ ∕ S’ and LOQ = 10·σ ∕ S’       (1) 
The obtained values were in line with literature data in each case (Supplementary file, Table 
S1). 
3.3.3. Precision 
The precision of the method was determined for each analyte in all matrices (Table 2). Intra-
assay precision, expressed as CV%, was evaluated by running six replicates, with values 
ranging between 1.14–4.25%, i.e., all of them were below 5%, in line with the values expected 
by the FDA [21]. Inter-assay precision was calculated by measuring the same samples used for 
the intra-assay precision with separate calibrations curves, after three days. The calculated 
values ranged between 1.11–6.37%, except for the 5-HT in the mouse brain sample, where a 
decrease of 52% was observed. This bias is higher than the maximum recommended value 
(15%) [21]. Due to the heterogeneity of the bioanalytical studies [35], there are many cases 
where the FDA proposed limits may not be applicable. In case of the brain samples of the 
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current study, the inter-assay precision measurements were done from the already homogenized 
samples, as we considered that brain sample regions cannot be divided into two homogenous 
parts compared to the supernatant samples. Therefore, the bias value draws attention to the 
necessity of brain homogenization right before the measurement in line with our currently 
applied laboratory practice. Accordingly, the freshly homogenized brain samples show stable 
concentration values (4.25 CV%). 
3.3.4. Accuracy 
Recovery studies were performed using spiked samples at three different concentration levels 
(LOQ, medium and high), representing the entire range of values used for the calibration curve, 
with three replicates for each concentration. Recovery percentages were calculated as R = 100 x 
[(Css-Cns)/Cspike], where Css is the concentration in the spiked homogenate sample, whereas Cns is 
the concentration of the homogenate native sample (without spiking) and Cspike is the added 
concentration. The obtained values ranged between 82.5-116% (Table 3), which are within 15% 
of the nominal value, except the LOQ-spiked recovery values, which did not deviate by more 
than 20%, as recommended by the official guidelines [20, 21]. 
3.4 Application of the developed method on different biological matrices 
The results of the measurements of the metabolites of interest from the assessed biological 
matrices (mouse plasma and brain, human plasma and CSF) with the developed and validated 
method are summarized in Table 4. All the reported data in the current study are in line with 
those obtained from the scientific literature [9,10,15,16,23–40]. 
 
4. Conclusion 
In summary, in this paper we report an improved HPLC-UVD and FLD method for the 
quantification of TRP and some of its metabolites (5-HT, KYN, and KYNA). The novelty of 
this study is the utilization of two different ISs, a widely applied one for the UVD and a novel 
one for the FLD, proved to be adaptable for measurements from all the four different biological 
matrices. Although the developed method, suitable for measurements from mouse plasma and 
human plasma and cerebrospinal fluid was not appropriate for measurements from the mouse 
brain samples, the method could be further improved with slight modifications (changing the 
pH from 6.2 to 5.8) to become applicable for the assessment of all the 4 above-mentioned 
compounds from mouse brain samples as well with a single run, which has not been published 
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before with HPLC-UVD and FLD (Supplementary file, Table S1). With regard to validation 
process, in addition to the achievement of appropriate selectivity, the linearity, LOD, LOQ, 
recovery and intra-assay precision values were all within the acceptable ranges provided by 
FDA and ICH [20, 21] and were in line with literature data proving the robustness of the 
method. The considerably high inter-assay value for 5-HT draws attention to the necessity of 
brain homogenization right before the measurement. Moreover, to demonstrate the applicability 
of the developed method, the above-mentioned metabolites were quantified in different 
biological matrices and all of the reported concentration values were within or near the ranges 
obtained from the scientific literature. In conclusion, a fit-for-purpose, simple and economical 
method with the simultaneous application of two ISs was developed with one-step sample 
preparation, acceptable running time and with applicability in either human or animal model 
studies. 
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Fig. 1. The partial metabolism of tryptophan through the kynurenine and serotonin pathways 
and the structure of the two internal standards used for the UV and fluorescence detectors. 
5-HT serotonin, IDO/TDO indoleamine 2,3-dioxygenase/ tryptophan 2,3-dioxygenase, KAT 
kynurenine aminotransferase, NAD
+
 nicotineamide adenine dinucleotide, TRP tryptophan.  
 
Fig. 2. Chromatograms of pooled mouse brain (A) and plasma (B), and human plasma (C) and 
cerebrospinal fluid (D) samples. UV chromatograms were obtained at 365 nm (B, C, D) and 360 
nm (A), whereas for the fluorescence chromatograms, we applied Ex/Em.: 246/396 nm for the 
first 7 minutes and 220/410 nm for the remaining time (running time: 11 min) (B, C, D). For the 
brain samples (A) 239/400 nm and 220/335 nm were applied (running time: 9 min). 
3NLT 3-nitro-L-tyrosine, 5-HT serotonin, HCA 4-hydroxyquinazoline-2-carboxylic acid, IS 
internal standard, KYN kynurenine, KYNA kynurenic acid 
 
Fig. 3. The UVD (A) and FLD (B) chromatograms of some pooled mouse brain samples, in 
different tested conditions. The X axis represents the running time of a sample, whereas the Y 
axis the detector response (mAU for the UVD, LU for the FLD). 3NLT 3-nitro-L-tyrosine, ACN 
acetonitrile, FLD fluorescence detector, HCA 4-hydroxyquinazoline-2-carboxylic acid, IS 
internal standard, KYN kynurenine, KYNA kynurenic acid, mAU mili absorbance unit, LU 
luminescence, UVD UV detector 
